Lymphoma

Pediatric cancer treatment has come a long way, but health problems persist in survivorship.

A recent report notes that certain health issues observed in young adult survivors are typically seen in much older individuals.

Updates from the annual meeting of the American Society of Hematology.

When considering a stem cell transplantation, patients with cancer must be willing to take a chance.

Cancer research updates from the San Antonio Breast Cancer Symposium and American Society of Hematology.

Childhood and young adult cancer survivors need fertility preservation information, but are they getting it from their oncologists?

When it comes to treating childhood Hodgkin lymphoma patients, less radiation might be better

A kid can bring out the best in people.

Creating Hope for Childhood Cancer

A new drug regimen that combines Treanda (bendamustine) and Rituxan (rituximab) has been shown to more than double progression-free survival time.

Minimizing and preventing late effects of stem cell transplantation.

GA101 could be the next step for patients who relapse on Rituxan (rituximab), a current standard of therapy.

Patients who are not suffering from symptoms of nonbulky follicular lymphoma are better off waiting until symptoms occur before beginning chemotherapy instead of undergoing maintenance Rituxan.

With the approval of Adcetris (brentuximab vedotin) for relapsed Hodgkin lymphoma, researchers are now examining whether the drug will help newly diagnosed patients.

The latest advancements in the treatment of Hodgkin lymphoma.

Research updates from the annual San Antonio Breast Cancer Symposium and American Society of Hematology.

Researchers are looking for genetic variations to determine which patients have an increased risk for a second cancer and should receive different treatments.

Although called a "good" cancer, Hodgkin lymphoma isn't always curable.

The latest in cancer prevention, diagnosis and treatment.

Online tool helps cancer survivors know what to look for years after treatment

Researchers showed that patients with nonsymptomatic, advanced follicular lymphoma (FL) benefit from Rituxan (rituximab) over watchful waiting.

A phase 2 trial presented at the American Society of Hematology in December could pave the way for a second approval for Istodax (romidepsin).

For Hodgkin lymphoma patients who progress after a stem cell transplant, two new treatments may bring new hope.

Updates from the annual meetings of the American Society of Hematology and the San Antonio Breast Cancer Symposium.